Share ownership AbbVie Inc.

ABBV

US00287Y1091

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 18:27:24 17/02/2026 GMT			5-day change	1st Jan Change
231.87 ^USD	+0.16%		+4.69%	+1.92%

04:03pm	Mubadala Investment Co PJSC reports share stake in Pfizer, AbbVie, dissolves in Merck, Dell	RE
03:19pm	HSBC Adjusts Price Target on AbbVie to $275 From $265, Maintains Buy Rating	MT

Share class: AbbVie Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,831,450,749	1,765,407,270 ( 96.39 %)	64,310,426 ( 3.511 %)	96.39 %

Major shareholders: AbbVie Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 10.23 %	180,779,699	10.23 %	40 316 M $
BlackRock Advisors LLC 6.38 %	112,751,940	6.38 %	25 145 M $
STATE STREET CORPORATION 4.58 %	80,940,931	4.58 %	18 051 M $
JPMorgan Investment Management, Inc. 2.974 %	52,566,779	2.974 %	11 723 M $
Geode Capital Management LLC 2.525 %	44,629,980	2.525 %	9 953 M $
Eaton Vance Management 2.266 %	40,041,939	2.266 %	8 930 M $
BlackRock Life Ltd. 1.921 %	33,949,276	1.921 %	7 571 M $
Norges Bank (13F) 1.452 %	25,668,761	1.452 %	5 724 M $
Capital Research & Management Co. (Global Investors) 1.438 %	25,408,200	1.438 %	5 666 M $
Charles Schwab Investment Management, Inc. 1.424 %	25,169,844	1.424 %	5 613 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Caixa DTVM SA 0.001073 %	303,442	0.001073 %	4 M $
XP Allocation Asset Management Ltda. 0.000003 %	986	0.000003 %	13 552 $

Breakdown by shareholder type

Institutional	59.54%
Other	8.14%
State Street Corp.	4.58%
Schweizerische Nationalbank	0.27%
Sumitomo Mitsui Trust Group, Inc.	0.23%
Manulife Financial Corp.	0.17%
Governments	0.13%
Swedbank AB	0.11%
Fifth Third Bancorp	0.08%
Danske Bank A/S	0.07%
Individuals	0.06%
SEI Investments Co.	0.06%
Menora Mivtachim Holdings Ltd.	0.06%
ABN AMRO Bank NV	0.05%
Zurich Insurance Group AG	0.05%
Skandinaviska Enskilda Banken AB	0.05%
ING Groep NV	0.04%
The Bank of Nova Scotia	0.04%
Regions Financial Corp.	0.04%
Cincinnati Financial Corp.	0.03%
Migdal Insurance & Financial Holdings Ltd.	0.02%
Cullen/Frost Bankers, Inc.	0.02%
Banco Bilbao Vizcaya Argentaria SA	0.02%
Peapack-Gladstone Financial Corp.	0.01%
Münchener Rückversicherungs-Gesellschaft AG	0.01%
The Allstate Corp.	0.01%
Silvercrest Asset Management Group, Inc.	0.01%
Hikari Tsushin, Inc.	0.01%
Banque Cantonale Vaudoise	0.01%
Intesa Sanpaolo SpA	0.01%
Hancock Whitney Corp.	0.01%
Unknown	26.05%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	55.57%
United Kingdom	7.38%
Canada	2.62%
Norway	1.58%
France	0.99%
Sweden	0.72%
Germany	0.72%
Japan	0.71%
Australia	0.59%
Switzerland	0.52%
Netherlands	0.47%
Denmark	0.4%
South Korea	0.3%
Luxembourg	0.29%
Hong Kong	0.23%
Italy	0.16%
Austria	0.12%
Spain	0.09%
Ireland	0.09%
Israel	0.08%
Belgium	0.06%
Individuals	0.06%
Finland	0.06%
Czech Republic	0.03%
New Zealand	0.03%
Liechtenstein	0.02%
Brazil	0.02%
Singapore	0.02%
China	0.01%
Slovenia	0.01%
South Africa	0.01%

Based on 1000 largest holdings

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.4%), Germany (2.6%), Japan (2%), Canada (1.9%), China (1.6%), France (1.4%), Spain (1%), the United Kingdom (0.9%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and other (9.7%).

Employees

55,000

Sector

Pharmaceuticals

Calendar

04-23 - Q1 2026 Earnings Release (Projected)

More about the company